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tion fluid; SELDI = surface-enhanced laser desorption and ionisation; TOF = time of flight.
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Introduction
In the adult nonpregnant, nonlactating breast, fluid is
secreted into the ducts and may contain exfoliated ductal
epithelial cells along with foam cells, lymphocytes and
neutrophils. Foam cells, thought to be of macrophage
lineage, are the most abundant cells found within ductal
fluid. They demonstrate CD68 macrophage-specific anti-
body staining and are usually negative for cytokeratin
markers [1,2].
The intraduct approach is an umbrella term for several differ-
ent techniques, including nipple aspiration (NA), ductal
lavage (DL) and duct endoscopy (DE), that allow sampling
of breast fluid and exfoliated epithelial cells – the cells at risk
for malignant transformation. DE also permits direct visual-
ization of the epithelial lining of the milk ducts. NA and DL
are minimally invasive techniques, whereas DE involves the
cannulation of the mammary duct system by a fibreoptic
ductoscope with an outer diameter typically less than 1 mm.
Women may be at significantly increased lifetime risk for
developing breast cancer because they have a significant
family history of breast or ovarian cancer or a number of
personal history factors. They may also be at heightened
risk because of carriage of a known deleterious mutation
in a highly penetrant breast cancer predisposition gene
such as BRCA1 or BRCA2, or other mutations in rarer
susceptibility alleles in genes including TP53, PTEN and
the recently described lower penetrance 1100delC muta-
tion in the cell cycle checkpoint kinase gene (CHEK 2)
[3–6]. Carriers of mutations in BRCA1/2 have a lifetime
risk for developing breast cancer of 60–85%, whereas
germ-line mutations in TP53 confer a lifetime risk for
breast cancer as high as 90% [7–9].
Currently, women who carry mutations in high-risk breast
cancer predisposition genes must make a difficult choice
between regular surveillance, risk-reducing surgery, or
taking part in trials of chemopreventive agents. The effec-
Review
Ductal approaches to assessment and management of women at
high risk for developing breast cancer
Imogen Locke1, Gillian Mitchell2 and Rosalind Eeles1
1Translational Cancer Genetics Team & Cancer Genetics Unit, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton,
Surrey, UK
2Family Cancer Centre, Peter MacCallum Cancer Centre, Victoria, Australia
Correspondence: Imogen Locke (e-mail: imogen.locke@icr.ac.uk)
Published: 26 January 2004
Breast Cancer Res 2004, 6:75-81 (DOI 10.1186/bcr759)
© 2004 BioMed Central Ltd (Print ISSN 1465-5411; Online ISSN 1465-542X)
Abstract
The ductal approach to breast cancer, encompassing nipple aspiration, ductal lavage and duct
endoscopy, allows assessment of breast ductal epithelial cells and their local microenvironment in a
graded process of increasing invasiveness. Samples of ductal epithelial cells sufficient for cytological
diagnosis may be safely collected, titres of individual proteins showing variation with breast cancer
status may be measured, and abnormal pathology within the breast ducts may be directly visualized.
Identification of surrogate molecular markers may facilitate early breast cancer detection, in conjunction
with cytological assessment, and be useful for individual prediction of breast cancer risk and
assessment of treatment response. However, the sensitivity and specificity of the ductal approach
require further evaluation. The small quantities of nipple aspiration fluid available for analysis, and
difficulties identifying and cannulating ducts remain important limitations of these techniques.
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tiveness of surveillance is uncertain and there are con-
cerns about the high incidence of interval breast cancers,
particularly in women under the age of 40 years and in
BRCA1/2 carriers [10]. Another concern is the potential
mutagenicity of repeated screening mammography in
women who have an inherited impairment in the ability to
repair double-stranded DNA breaks.
There is considerable interest in alternative screening
tools in this group of women, such as breast magnetic res-
onance imaging [11]. The ductal approach is currently
being evaluated as a reproducible method of gaining mini-
mally invasive access to epithelial cells. Subsequent cyto-
logical and/or molecular analysis of these cells may inform
individual breast cancer risk assessment or even permit
early diagnosis of cancer while avoiding the use of ionizing
radiation.
Application of the ductal approach in high-
risk women
Identification of high-risk women and estimation of their
breast cancer risk is currently based on the use of vali-
dated mathematical models such as the Gail and the
Claus models [12,13]. The intraduct approach, with its
ability to examine directly those cells that are most at risk
for malignant transformation and their surrounding milieu,
intuitively offers the potential for refining personal risk esti-
mates, thus aiding clinical management decisions, and it
may facilitate detection of early breast cancer. This would
be particularly useful in counselling women at high risk for
developing breast cancer, in whom epidemiological
models of risk assessment and current screening tools
have well recognized limitations [10,14]. New insights into
the interactions within breast tissue that are involved in the
multistep process of carcinogenesis may also be gained.
Chemoprevention is an expanding area of interest,
although four trials of tamoxifen chemoprevention in
women at increased risk for developing breast cancer
[15–18] yielded conflicting results. Trials to assess the
efficacy of chemopreventive drugs take many years to
perform when the development of breast cancer or breast
cancer mortality are used as the primary end-points.
Markers within ductal fluid or cytogenetic changes within
ductal epithelial cells that directly reflect early response to
therapy (biomarkers) would provide a more immediate and
desirable end-point for chemoprevention trials in high-risk
women.
Nipple aspirate cytology
NA is the simplest and least invasive of the methods for
sampling the intraduct environment. Following cleansing
with an alcohol impregnated swab, the woman is asked to
massage her breast from the base toward the nipple.
Suction is then exerted on the nipple using a modified
breast pump, and in most women droplets of nipple aspi-
rate fluid (NAF) will appear on the nipple surface that may
be collected into capillary tubes. The sample from one
breast is generally pooled as a consequence of the small
volumes of NAF produced.
Cytological assessment of spontaneous nipple secretions
and NAF are not new techniques; Papanicolaou and
coworkers [19] demonstrated that nipple fluid could be
aspirated from healthy nonlactating, nonpregnant women,
and his cytopathological examination of samples from 613
breasts of 412 women without breast symptoms revealed
one occult breast carcinoma. Similarly, Sartorius and
coworkers [20] reported the diagnosis, by nipple aspirate
cytology alone, of seven clinically and mammographically
occult carcinomas among 1503 women.
NA does not yield fluid in all women, with investigators
reporting success rates of between 38% and 99%
[21,22]. Typically, 20–30 µl of NAF may be collected but
reported volumes range from 1 µl to over 200 µl [23,24].
The proportion of specimens containing adequate
numbers of epithelial cells for cytological diagnosis
(>10 cells) is highly variable, but success rates among
fluid-yielders of up to 95% have been reported [23]. Aspi-
rates from women with clinical evidence of benign breast
disease tend to be more cellular [25]. The percentage of
successful aspirations is greatest in women aged
between 35 and 50 years, and factors associated with
increased yield of nipple aspiration include early age at
menarche, Caucasian (as opposed to Asian) ethnicity, and
a history of parity or lactation [24]. The effects of age
appeared to be independent of menopausal status. Prior
breast irradiation has been reported to reduce the rate of
successful nipple aspiration [23].
Although early work demonstrated occasional detection of
malignant cells, one of the limitations of nipple aspirate
cytology as a diagnostic tool in early breast cancer is the
low percentage of specimens that contain cancer cells,
even when the aspirate is obtained from a known cancer-
bearing breast; sensitivities of 4% and 21% were reported
in two studies [26,27]. The low sensitivity may relate in
part to the anatomical obstruction of the breast ducts by
tumour, preventing exfoliated malignant cells from reach-
ing the nipple and/or breaching the integrity of the duct to
permit leakage of ductal fluid. The sensitivity of NA cytol-
ogy in detecting preinvasive breast disease has been
reported to be higher than in established invasive breast
cancer [26].
Ductal lavage cytology
DL is a minimally invasive procedure in which a fine plastic
microcatheter is threaded into the nipple duct orifices to a
maximum depth of 1.5 cm. NA is used to identify fluid-pro-
ducing ducts, because these are the most likely to be suc-
cessfully cannulated. Normal saline is instilled through the77
catheter, after which the effluent is recovered by simulta-
neous compression of the breast and aspiration. Although
more invasive than NA, DL has the advantage of allowing
collection of duct-specific samples. However, failure to
cannulate successfully all nipple ducts is a limitation of this
technique, particularly if it were to be used as a screening
tool for breast cancer.
In a multicentre trial of 507 women at increased risk for
breast cancer [28], DL was compared with NA with
respect to safety, tolerability and ability to detect atypical
epithelial cells. High-risk women were defined as a 5-year
Gail risk for developing invasive breast cancer of at least
1.7%, a prior history of invasive breast cancer or carci-
noma in situ, or known carriage of a mutation in either the
BRCA1 or  BRCA2 gene (although only three women
were BRCA1 or BRCA2 mutation carriers, accounting for
<1% of the study population). Of the nipple aspirate
samples 27% were adequate for cytological diagnosis
(defined as >10 epithelial cells per slide), as compared
with 78% of DL samples. The median cellularity of DL
specimens was 135 000 per duct (range 43–492000),
and DL specimens contained significantly more epithelial
cell clusters than did the corresponding NAF, in which the
median epithelial cell count per breast was 120 (range
10–74300). The comparative detection rates of marked
atypia for DL and NA were 6% and 3%, respectively. Mild
atypia (some atypical features such as nuclear pleiomor-
phism, increased nuclear:cytoplasmic ratio and loss of cel-
lular cohesiveness in an otherwise benign aspirate) was
detected in 17% of the DL samples, as compared with
6% of the NA samples. Malignant cells were found in
nipple aspirates from two women (<1%), and these were
the same two women who were found to have malignant
cells on DL.
Duct endoscopy
Breast DE is the most recent of the intraduct techniques
to have been developed, and it permits direct visualization
of the proximal ductal tree. It is currently limited by the
technical difficulties of reliably identifying duct orifices and
obtaining tissue biopsies. The application of DE for routine
outpatient screening of high-risk women has not been
assessed, and indeed much remains unknown about the
sensitivity and specificity of DE for detection of early
breast cancer. Ductal washing can be harvested during
ductoscopy and cytopathological findings correlated with
subsequent histopathogy in women undergoing breast
surgery [29]. Images of ductal abnormalities may also be
recorded using video. An application of DE being currently
explored is its use to guide the extent of lumpectomy for
management of breast cancer. DE has been reported to
highlight substantial amounts of intraductal disease not
suspected on preoperative mammography and ultrasound,
resulting in the reduction of the surgical positive margin
rate from 23.5% to 5% [30].
The prognostic value of ductal epithelial cell
atypia
In a retrospective cohort study, the relative risk for devel-
oping invasive breast carcinoma in women found to have
atypical ductal hyperplasia (ADH) on breast biopsy is
4.3 times that in the general population, and when com-
bined with a positive family history the relative risk for inva-
sive breast cancer rises to 9.7 [31]. Similarly, in a nested
case–control study [32] the relative risk for breast cancer
in women with ADH on biopsy was 4.3, and there was a
synergistic increase in breast cancer relative risk to 22
when ADH was combined with a first-degree family history
of breast cancer.
Wrensch and coworkers [33] studied the long-term prog-
nostic significance of nipple aspirate cytology for breast
cancer development prospectively in a cohort of 2701
Caucasian volunteer women from the San Francisco Bay
area who were followed for a median of 12.7 years. The rel-
ative risk for breast cancer in women with cellular atypia in
NAF was fivefold higher than in women who did not yield
fluid and three times higher than in women with normal
NAF cytology. The relative risk was even greater for women
under 55 years of age. Women with atypia and a first-
degree family history of breast cancer were sixfold more
likely to develop breast cancer compared with women with
atypia but no family history of breast cancer. Extended
follow up after a median of 21 years of an expansion of this
cohort of women [34] confirmed these findings, with an
increased relative risk for developing breast cancer of 2.8
for women with atypia compared with women from whom
nipple aspirate fluid could not be obtained.
Random periareolar fine needle aspiration cytology is
another method that has been developed to sample the
breast ductal epithelium. In a study of 484 women at
increased risk for developing breast cancer [35], both
hyperplasia with atypia and Gail model risk estimates were
found to be independent predictors of breast cancer
development, with atypia increasing the relative risk by a
factor of five. In summary, the relative risks for developing
breast cancer associated with cytological atypia, whether
identified by NA or by random periareolar fine needle aspi-
ration, are similar to the increased risk for breast cancer
conferred by the histopathological finding of ADH on
breast biopsy. However, the long-term significance for
individuals of atypia within DL fluid, particularly mild cellu-
lar atypia, is yet to be clarified. The ability of the ductal
approach to detect early breast cancer using cytological
criteria alone appears to be low and current research is
directed toward identifying molecular markers that, in com-
bination with cell morphology, may be of utility in the
assessment and management of women at increased risk
for developing breast cancer. It may be that the ductal
approach is most useful in breast cancer risk prediction
rather than detection of early breast cancer.
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Candidate biomarkers in nipple aspiration
fluid
One approach to the search for complementary biomark-
ers of breast cancer risk has been to measure individual
molecules in NAF, often proteins with established value as
serum tumour markers, and to study their variation with
disease status. Prostate-specific antigen, a serine pro-
tease, is a useful serum marker for the diagnosis and man-
agement of prostate cancer, and was recently found to be
expressed at high levels in NAF [36–38]. Although Sauter
and coworkers [38] reported lower levels of prostate-spe-
cific antigen in NAF from breasts with cancer or precan-
cerous mastopathy, others have failed to show a similar
variation with tumour status [39]. Carcinoembryonic
antigen (CEA) is measurable in NAF at considerably
higher concentrations than in serum, and in one study [39]
CEA titres were significantly higher in untreated cancer-
ous breasts than in tumour-free breasts, giving a sensitivity
for CEA as a candidate biomarker for breast cancer detec-
tion of 48% and a specificity of 75%. In a study of women
with unilateral invasive breast cancer [40], levels of
expression of the HER-2/neu extracellular domain in NAF
were found to be significantly higher in the breast with
cancer than in the contralateral normal breast, but this dif-
ference was restricted to women with HER-2/neu over-
expressing tumours.
Growth factors play important roles in the control of
epithelial cell proliferation, and they are therefore an
attractive potential source of biomarkers for evaluation. It
is feasible to measure epidermal growth factor and trans-
forming growth factor-α in NAF from healthy women
[41,42]. Angiogenic growth factors, including basic
fibroblast growth factor and vascular endothelial growth
factor, have been the subject of recent studies; high levels
of the former in NAF exhibit an association with breast
cancer status independent of race and menopausal status
[43,44]. The matrix metalloproteinases (MMPs), which are
involved in degradation and remodelling of the extracellu-
lar matrix and in tumour invasion and metastasis, were
recently measured in NAF [45]; higher mean concentra-
tions of MMP-2 and MMP-9 were present in fluid from
cancer-containing breasts than in fluid from benign or
healthy breasts.
There is a vast array of individual molecules worthy of
further investigation as candidate biomarkers of malig-
nancy. These are involved at all stages of tumour genesis
and progression from self-sufficiency in growth signals,
evasion of apoptosis, and sustained angiogenesis, to
tissue invasion and metastasis. Limitations in sensitivity
and specificity of individual markers may be partially over-
come by considering a panel of molecules that are individ-
ually predictive of breast cancer risk. The degree of
overlap between ranges in cancerous and healthy breasts,
together with the small amounts of NAF available for multi-
ple directed assays, are other difficulties that make global
approaches to biomarker discovery such as proteomics
attractive alternative strategies.
Genetic instability in ductal epithelial cells
The presence of numerical aberrations of chromosomes 1,
8 and 17 has been correlated with the multistage process
of breast cancer tumourigenesis and progression. These
may precede morphological changes in the ductal epithe-
lial cells [46–49]. Fehm and coworkers [47] found that
92% of 74 primary breast cancers showed aneusomy for
chromosomes 1, 8 or 17, whereas Botti and coworkers
[46] demonstrated aneusomy of chromosomes 1 and 17
in fresh imprints of primary breast cancers and in biopsies
of adjacent uninvolved tissue in 66.7% of patients. Similar
patterns of chromosomal aneusomy were seen in the con-
tralateral breasts of women who had previously had breast
cancer, suggesting a field effect of genomic instability
compared with benign controls [46].
The sensitivity and specificity for breast cancer detection
of conventional cytology, in comparison with cytogenetic
findings of interphase fluorescent in situ hybridization
(FISH) using centromeric probes, were evaluated in DL
fluid [50]. Cytology was abnormal in seven out of 15
evaluable ductal lavages obtained from cancerous
breasts, as compared with four out of 19 evaluable
lavages from paired benign cases, giving a sensitivity and
specificity for cytology alone of 47% and 79%, respec-
tively. Interphase FISH showed significant gains of chro-
mosomes 1, 8, 11 and/or 17 (more than three standard
deviations greater than the mean percentage values of
monosomic and polysomic cells in the benign samples) in
10 out of 14 evaluable lavages from the cancerous
breasts, as compared with two of 18 samples from the
benign cases, giving a sensitivity and specificity for FISH
of 71% and 89%, respectively.
A further study, in which cytology and FISH were applied
to ductal lavage specimens, was conducted in women
with nipple discharge and abnormal ductography and/or
fibreoptic ductoscopy [51]. None of the samples collected
from 54 benign cases showed aneusomy for chromo-
somes 1, 11 or 17, giving a specificity of 100%, whereas
aneusomy for at least one of these three chromosomes
was seen in all six malignant cases examined. These
studies demonstrated the feasibility of analyzing ductal
epithelial cells for chromosomal abnormalities, and in the
future cytogenetic findings may usefully improve the dis-
criminatory value of cytology for the definitive diagnosis of
malignancy.
DNA hypermethylation as a biomarker of
malignancy
The expression of a number of genes in primary breast
cancer has been shown to be silenced by hypermethyla-
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tion of promoter sequences [52,53]. Evron and coworkers
[54] used methylation-specific polymerase chain reaction
(MSP) to search for breast cancer-associated changes in
patterns of DNA methylation. Those investigators defined
a set of three genes (Cyclin D2, Twist, RARβ) that were
hypermethylated in 96% of invasive breast carcinomas
and 57% of ductal carcinoma in situ in surgically excised
specimens from women with primary breast tumours. The
application of MSP to the detection of malignant epithelial
cells in ductal fluid was subsequently investigated. At least
one methylated marker was found in 17 out of 20 samples
of the irrigation fluid from women who underwent breast
DE immediately before definitive surgery for biopsy-proven
breast cancer. DL fluid was also obtained from 56 asymp-
tomatic high-risk women (Gail risk ≥1.7, previous con-
tralateral breast cancer, or carrier of a BRCA1 or BRCA2
gene mutation), in whom there were no suspicious find-
ings on mammography or physical examination, and ana-
lyzed for methylated markers. Forty-five samples were
classified as benign, five samples were classified as mildly
atypical, and six samples exhibited severe atypia or were
frankly malignant by cytopathological criteria alone. Four
out of the six severely atypical or malignant samples were
also identified by MSP (sensitivity 67%), whereas only five
out of the 45 benign samples were positive for methylated
markers (specificity 89%). Two women who had both
abnormal cytology and at least one methylated marker in
ductal lavage fluid were subsequently found to have
pathologically confirmed breast cancer.
Proteomics and high-throughput biomarker
discovery
Growing interest in the global expression of proteins in
biological systems (the so-called proteome) has arisen
because proteins are the workhorses of most cellular func-
tions. Unique protein expression profiles associated with
disease states may reflect not only changes at the gene
expression level but also post-translational modifications.
High-throughput proteomic technologies are being devel-
oped, such as surface-enhanced laser desorption and ion-
ization (SELDI). This novel form of mass spectrometry, in
which proteins are selectively adsorbed to coated metal
‘chips’, utilizes time of flight (TOF) mass spectrometry to
analyze proteins that interact with the chip surface after
washing under different conditions to remove unbound
protein. SELDI-TOF overcomes some of the problems of
labour intensive sample separation and requires only
microlitre quantities of biological fluids, but it does not
provide routine peptide sequence information.
A number of recent studies have demonstrated the
promising application of proteomics to samples of NAF,
leading to the generation of ‘fingerprints’ representing pro-
teins that are differentially expressed in cancerous breasts
and normal breasts and worthy of further evaluation as
biomarkers of malignancy [55–57]. Using SELDI-TOF
mass spectrometry to examine NAF from 12 women with
breast cancer and 15 healthy control women, proteomic
patterns were identified that appeared to be discriminatory
between the two groups [55]. Similarly, Sauter and
coworkers [56] used the SELDI technique to perform a
proteomic analysis over the 5–40 kDa range and identified
five differentially expressed protein peaks in NAF from
20 women with breast cancer and 13 women with healthy
breasts, the two most discriminatory of which had molecu-
lar weights of 6500 Da and 15940 Da. The former peak
has been suggested to represent epithelin. A further differ-
entially expressed peak of 28100 Da has been putatively
identified as a member of the kallikrein family.
A preliminary gel-based proteomics study using two-
dimensional PAGE detected between 1280 and 1649
separate protein spots in NAF. Up to 202 qualitative differ-
ences were found between NAF taken from the diseased
breast of three women with unilateral breast cancer and
the contralateral normal breast, whereas in one healthy
woman only five protein spots were different between left
and right breasts [57]. Progress is being made toward
characterizing the full proteome of NAF, and hence the
exact identification of the proteins responsible for the dif-
ferential patterns seen using both gel-based and gel-free
proteomic techniques. A recent report [58] definitively
identified 64 proteins in the moderately abundant and
abundant ranges within NAF, 15 of which were previously
reported to vary with breast cancer status in serum or
tumour tissue, and include among others cathepsin D and
osteopontin.
Conclusion
The intraduct approach to risk assessment and early diag-
nosis of breast cancer in high-risk women has many theo-
retical attractions; however, the specificity and sensitivity
of these techniques remain important limitations. Although
early studies demonstrated that NA and DL are feasible
and safe techniques for retrieving epithelial cells, the rela-
tionship between the various degrees of cellular atypia
and the underlying process of breast cancer tumourigene-
sis is not completely understood. NA has the advantage of
being well tolerated, easy to perform and inexpensive, but
it is limited by the small amounts of aspirate available for
analysis, the relatively low cellular yield and the fact that
not all women are fluid yielders. DL, although more inva-
sive, produces material that is much more cellular than
NAF and allows duct-specific sampling. However, the DL
fluid is diluted with a variable quantity of saline, which may
complicate quantitative analysis of biomarkers. DE is the
most labour intensive of the intraduct techniques with the
greatest resource implications, and therefore in practice it
may be best suited to the further investigation of women in
whom cellular atypia has already been identified, in con-
junction with clinical and radiological assessment. These
complexities, along with the requirement for regular inter-
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vention and follow up, may affect compliance rates among
high-risk women.
Recent developments in the fields of genomics and pro-
teomics, and the advent of high throughput biotechnolo-
gies give hope that biomarker patterns associated with
disease states will be defined. These patterns could com-
plement the traditional cytological assessment of cell mor-
phology, improving the predictive and diagnostic value of
the intraduct approach. The intraduct approach may help
to refine a personalized breast cancer risk assessment,
which would be of particular importance to high-risk
women who face difficult decisions about risk manage-
ment options. Furthermore, sampling the ductal epithelial
cells and their local microenvironment may also identify
markers of early response to therapy that act as surrogate
end-points in chemoprevention trials. Studies have shown
early promise in identifying surrogate markers of breast
cancer risk, including multiple molecules that are involved
at all stages of cancer development and progression, epi-
genetic changes such as hypermethylation of promoter
sequences, and differential patterns of protein expression.
Validation of these potential molecular markers of breast
cancer risk and further evaluation of the ductal approach
to establish its sensitivity and specificity in detecting early
breast cancer is required. The intraduct approach is
beginning to show value in documenting the presence and
extent of ductal epithelial proliferation within breast tissue,
informing the assessment and management of high-risk
women and providing new insights into the biology of
breast cancer.
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